Rapid detoxification of benzodiazepine or Z-drugs dependence using acetylcholinesterase inhibitors

Medical Hypotheses

Volumn 83, Issue 1, 2014, Pages 108-110

  Lin, Shih Ku ^a,b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; FLURAZEPAM; GALANTAMINE; HYPNOTIC AGENT; QUETIAPINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; ZOLPIDEM; ACETYLCHOLINESTERASE; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; BEDTIME DOSAGE; BENZODIAZEPINE DEPENDENCE; CASE REPORT; DIARRHEA; DRUG DETOXIFICATION; DRUG DOSE INCREASE; DRUG HALF LIFE; FEMALE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MIDDLE AGED; MORNING DOSAGE; NAUSEA; PSYCHOPHARMACOTHERAPY; TREATMENT RESPONSE; VOMITING; DRUG EFFECTS; SUBSTANCE-RELATED DISORDERS;

ACETYLCHOLINESTERASE; BENZODIAZEPINES; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS;

EID: 84901024326     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.03.032     Document Type: Article

References (30)

1. Ohayon M.M., Lader M.H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002, 63:817-825.
2. Holm K.J., Goa K.L. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000, 59:865-889.
3. Soyka M., Bottlender R., Moller H.J. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000, 33:138-141.
4. Victorri-Vigneau C., Dailly E., Veyrac G., Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007, 64:198-209.
5. Victorri-Vigneau C., Feuillet F., Wainstein L., Grall-Bronnec M., Pivette J., Chaslerie A., et al. Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. Eur J Clin Pharmacol 2013, 69:1965-1972.
6. Brenner P.M., Wolf B., Rechlin T., Kauert G., Ruther E., Hippius H. Benzodiazepine dependence: detoxification under standardized conditions. Drug Alcohol Depend 1991, 29:195-204.
7. Lader M., Tylee A., Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009, 23:19-34.
8. Alexander B., Perry P.J. Detoxification from benzodiazepines: schedules and strategies. J Subst Abuse Treat 1991, 8:9-17.
9. Conell L.J., Berlin R.M. Withdrawal after substitution of a short-acting for a long-acting benzodiazepine. JAMA 1983, 250:2838-2840.
10. Tyrer P., Owen R., Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet 1983, 1:1402-1406.
11. Streel E., Verbanck P. Ultra-rapid opiate detoxification: from clinical applications to basic science. Addict Biol 2003, 8:141-146.
12. Singh J., Basu D. Ultra-rapid opioid detoxification: current status and controversies. J Postgrad Med 2004, 50:227-232.
13. Gowing L., Ali R., White J.M. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev 2010, CD002022.
14. Croissant B., Grosshans M., Diehl A., Mann K. Oxcarbazepine in rapid benzodiazepine detoxification. Am J Drug Alcohol Abuse 2008, 34:534-540.
15. Amrein R., Leishman B., Bentzinger C., Roncari G. Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology. Med Toxicol Adverse Drug Exp 1987, 2:411-429.
16. Quaglio G., Pattaro C., Gerra G., Mathewson S., Verbanck P., Des Jarlais D.C., et al. High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res 2012, 198:457-462.
17. Mintzer M.Z., Griffiths R.R. Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure. Psychopharmacology 2005, 178:259-267.
18. Rosenberg H. Letter: physostigmine reversal of sedative drugs. JAMA 1974, 229:1168.
19. Di Liberti J., O'Brien M.L., Turner T. The use of physostigmine as an antidote in accidental diazepam intoxication. J Pediatr 1975, 86:106-107.
20. Larson G.F., Hurlbert B.J., Wingard D.W. Physostigmine reversal of diazepam-induced depression. Anesth Analg 1977, 56:348-351.
21. Bidwai A.V., Stanley T.H., Rogers C., Riet E.K. Reversal of diazepam-induced postanesthetic somnolence with physostigmine. Anesthesiology 1979, 51:256-259.
22. Nilsson E., Himberg J.J. Physostigmine for post-operative somnolence after diazepam-nitrous oxide anaesthesia. Acta Anaesthesiol Scand 1982, 26:9-14.
23. Walz M.A., Davis W.M. Experimental diazepam intoxication in rodents: physostigmine and naloxone as potential antagonists. Drug Chem Toxicol 1979, 2:257-267.
24. Ongini E., Parravicini L., Bamonte F. Effects of physostigmine on benzodiazepine toxicity. Arch Int Pharmacodyn Ther 1981, 253:164-176.
25. Boast C.A., Bernard P.S., Barbaz B.S., Bergen K.M. The neuropharmacology of various diazepam antagonists. Neuropharmacology 1983, 22:1511-1521.
26. Haefely W. Antagonists of benzodiazepines. Encephale 1983, 9:143B-150B.
27. Coelho F., Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2001, CD001499.
28. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, CD005593.
29. Scarr E., Gibbons A.S., Neo J., Udawela M., Dean B.l. Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci 2013, 7:55.
30. Sullivan M.A., Chen H., Morikawa H. Recurrent inhibitory network among striatal cholinergic interneurons. J Neurosci 2008, 28:8682-8690.